Loss of Expression and Promoter Methylation of SLIT2 Are Associated with Sessile Serrated Adenoma Formation

English version České info

Serrated adenomas form a distinct subtype of colorectal pre-malignant lesions that may progress to malignancy along a different molecular pathway than the conventional adenoma-carcinoma pathway. Previous studies have hypothesised that BRAF mutation and promoter hypermethylation plays a role, but the evidence for this is not robust. We aimed to carry out a whole-genome loss of heterozygosity analysis, followed by targeted promoter methylation and expression analysis to identify potential pathways in serrated adenomas. An initial panel of 9 sessile serrated adenomas (SSA) and one TSA were analysed using Illumina Goldengate HumanLinkage panel arrays to ascertain regions of loss of heterozygosity. This was verified via molecular inversion probe analysis and microsatellite analysis of a further 32 samples. Methylation analysis of genes of interest was carried out using methylation specific PCR (verified by pyrosequencing) and immunohistochemistry used to correlate loss of expression of genes of interest. All experiments used adenoma samples and normal tissue samples as control. SSA samples were found on whole-genome analysis to have consistent loss of heterozygosity at 4p15.1–4p15.31, which was not found in the sole TSA, adenomas, or normal tissues. Genes of interest in this region were PDCH7 and SLIT2, and combined MSP/IHC analysis of these genes revealed significant loss of SLIT2 expression associated with promoter methylation of SLIT2. Loss of expression of SLIT2 by promoter hypermethylation and loss of heterozygosity events is significantly associated with serrated adenoma development, and SLIT2 may represent a epimutated tumour suppressor gene according to the Knudson “two hit” hypothesis.

Vyšlo v časopise: Loss of Expression and Promoter Methylation of SLIT2 Are Associated with Sessile Serrated Adenoma Formation. PLoS Genet 9(5): e32767. doi:10.1371/journal.pgen.1003488
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003488

Souhrn

Zdroje

1. LeggettB, WhitehallV Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 138: 2088–2100.

2. SnoverDC, JassJR, Fenoglio-PreiserC, BattsKP (2005) Serrated polyps of the large intestine: a morphologic and molecular review of an evolving concept. Am J Clin Pathol 124: 380–391.

3. RexDK, AhnenDJ, BaronJA, BattsKP, BurkeCA, et al. (2012) Serrated Lesions of the Colorectum: Review and Recommendations From an Expert Panel. Am J Gastroenterol

4. TorlakovicEE, GomezJD, DrimanDK, ParfittJR, WangC, et al. (2008) Sessile serrated adenoma (SSA) vs. traditional serrated adenoma (TSA). Am J Surg Pathol 32: 21–29.

5. CarrNJ, MahajanH, TanKL, HawkinsNJ, WardRL (2009) Serrated and non-serrated polyps of the colorectum: their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma. J Clin Pathol 62: 516–518.

6. ChanTL, ZhaoW, LeungSY, YuenST (2003) BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res 63: 4878–4881.

7. JassJR, BakerK, ZlobecI, HiguchiT, BarkerM, et al. (2006) Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a ‘fusion’ pathway to colorectal cancer. Histopathology 49: 121–131.

8. O'BrienMJ, YangS, MackC, XuH, HuangCS, et al. (2006) Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol 30: 1491–1501.

9. VandrovcovaJ, Lagerstedt-RobinssonK, PahlmanL, LindblomA (2006) Somatic BRAF-V600E mutations in familial colorectal cancer. Cancer Epidemiol Biomarkers Prev 15: 2270–2273.

10. FuB, YachidaS, MorganR, ZhongY, MontgomeryEA, et al. (2012) Clinicopathologic and genetic characterization of traditional serrated adenomas of the colon. Am J Clin Pathol 138: 356–366.

11. KimGE, LeeKH, ChoiYD, LeeJS, LeeJH, et al. (2011) Detection of Slit2 promoter hypermethylation in tissue and serum samples from breast cancer patients. Virchows Arch 459: 383–390.

12. ZhouWJ, GengZH, ChiS, ZhangW, NiuXF, et al. (2011) Slit-Robo signaling induces malignant transformation through Hakai-mediated E-cadherin degradation during colorectal epithelial cell carcinogenesis. Cell Res 21: 609–626.

13. BeggsAD, JonesA, El-BahwaryM, AbulafiM, HodgsonSV, et al. (2012) Whole-genome methylation analysis of benign and malignant colorectal tumours. J Pathol

14. ShivapurkarN, MaitraA, MilchgrubS, GazdarAF (2001) Deletions of chromosome 4 occur early during the pathogenesis of colorectal carcinoma. Hum Pathol 32: 169–177.

15. ShivapurkarN, SoodS, Wistuba, II, VirmaniAK, MaitraA, et al. (1999) Multiple regions of chromosome 4 demonstrating allelic losses in breast carcinomas. Cancer Res 59: 3576–3580.

16. ShivapurkarN, VirmaniAK, WistubaII, MilchgrubS, MackayB, et al. (1999) Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma. Clin Cancer Res 5: 17–23.

17. DallolA, Da SilvaNF, ViacavaP, MinnaJD, BiecheI, et al. (2002) SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res 62: 5874–5880.

18. DallolA, MortonD, MaherER, LatifF (2003) SLIT2 axon guidance molecule is frequently inactivated in colorectal cancer and suppresses growth of colorectal carcinoma cells. Cancer Res 63: 1054–1058.

19. PrasadA, ParuchuriV, PreetA, LatifF, GanjuRK (2008) Slit-2 induces a tumor-suppressive effect by regulating beta-catenin in breast cancer cells. J Biol Chem 283: 26624–26633.

20. PrasadA, QamriZ, WuJ, GanjuRK (2007) Slit-2/Robo-1 modulates the CXCL12/CXCR4-induced chemotaxis of T cells. J Leukoc Biol 82: 465–476.

21. ForcetC, YeX, GrangerL, CorsetV, ShinH, et al. (2001) The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation. Proc Natl Acad Sci U S A 98: 3416–3421.

22. AzuaraD, Rodriguez-MorantaF, de OcaJ, SanjuanX, GuardiolaJ, et al. (2012) Novel methylation panel for the early detection of neoplasia in high-risk ulcerative colitis and Crohn's colitis patients. Inflamm Bowel Dis

23. JonesPA, LairdPW (1999) Cancer epigenetics comes of age. Nat Genet 21: 163–167.

24. LiLC, DahiyaR (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427–1431.

25. HallGL, ShawRJ, FieldEA, RogersSN, SuttonDN, et al. (2008) p16 Promoter methylation is a potential predictor of malignant transformation in oral epithelial dysplasia. Cancer Epidemiol Biomarkers Prev 17: 2174–2179.

26. ParrellaP, la TorreA, CopettiM, ValoriVM, BarbanoR, et al. (2009) High specificity of quantitative methylation-specific PCR analysis for MGMT promoter hypermethylation detection in gliomas. J Biomed Biotechnol 2009: 531692.

27. ShawRJ, Akufo-TettehEK, RiskJM, FieldJK, LiloglouT (2006) Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing. Nucleic Acids Res 34: e78.